Phase 2 N=108 New Medication Treatment for Stimulant Dependence
Cocaine Dependence
Primary: Cocaine Use by Self-report — 67; 67 Percent of cocaine-free (abstinent)days — p=0.972
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=31 Carvedilol for Psychostimulant Dependence
Cocaine Dependence · Cocaine Withdrawal
Primary: Urine Toxicology Screens — 38.33; 41.85 percentage of cocaine negative urines — p=0.05
Phase 2 N=81 Medications for Stopping Cocaine Dependence and Preventing Relapse
Cocaine Abuse · Cocaine-Related Disorders
Primary: Mean Percentage of Cocaine-positive Urines Over Course of 12 Week Treatment in Subgroup Achieving Abstinence at Baseline — 31; 28; 47; 35 Mean % of cocaine-positive urines
Phase 2 N=22 Doxazosin for Psychostimulant Dependence
Methamphetamine or Cocaine Dependence
Primary: Change in Psychostimulant-positive Urines Over Time — .6; .41; .79; .25 proportion of psychostimulant-pos urines — p=0.05
N/A N=78 Stress, Distress Intolerance, and Drug Dependence
Substance Dependence
Primary: Percentage of Positive Toxicology Swabs for Illicit Substances — 81.3; 79.1; 86.2; 82.3 percentage of positive toxicology screen
Phase 4 N=40 Effects of Modafinil in Methamphetamine Dependence
Methamphetamine Dependence
Primary: Percentage of Participants With Methamphetamine-positive Urine Drug Screens — 85; 65 Percentage of participants
Phase 2 N=35 Studying Amphetamine Withdrawal in Humans
Methamphetamine Dependence
Primary: Measure of Methamphetamine Withdrawal — 3.7283; 10.056 units on a scale
Phase 2 N=43 Treatment of Cocaine Dependence With Lisdexamfetamine
Cocaine Dependence
Primary: Cocaine-positive Urine Results — 86.5; 92.4 percentage of BE urine tests
Phase 2 N=73 Effectiveness of Modafinil and D-amphetamine in Treating Cocaine Dependent Individuals
Cocaine-Related Disorders
Primary: Cocaine Use as Assessed by the Treatment Effectiveness Score (TES), Which is the Total Number of Cocaine-negative Urines During Treatment — 9.25; 6.09; 6; 4.91 number of…
Phase 2 N=70 Treatment for Cannabis Withdrawal and Dependence
Cannabis Dependence
Primary: Change From Week 0 in Cannabis Use Using Urinary CN-THCCOOH Levels at Week 8 — -334.21; -359.95 ng/mg
N/A N=40 Bupropion in the Treatment of Methamphetamine Dependence
Methamphetamine Use Disorder
Primary: Estimate the Treatment Effect of Bupropion for Methamphetamine (Meth) Dependence. — 5.6; 6.0 days
Phase 2 N=81 A Placebo-Controlled Study of Mixed Amphetamine Salts and Topiramate for the Treatment of Cocaine Dependence
Cocaine Dependence
Primary: Three Weeks of Continuous Cocaine Abstinence as Measured by Urine Toxicology and Self Report Based on Time Line Follow Back — 13; 7 participants — p==.05
Phase 3 N=104 Citicoline Treatment of Methamphetamine Dependence
Methamphetamine Dependence
Primary: Methamphetamine Dependent Subjects Treated With Citicoline vs Placebo — 0.3025; 0.3850 total amount consumed in grams
Early Phase 1 N=18 Impact of Sustained Release d-Amphetamine on Choice Between Cocaine and a Non-Drug Reinforcer
Active Cocaine Users
Primary: The Number of Times Cocaine Was Selected in the Presence of a Monetary Reward Alternative — 0.06; 0.94; 0.75; 0.88 cocaine choices
Phase 2 N=13 Clinical Efficacy of Atomoxetine for Methamphetamine Dependence
Methamphetamine Dependence
Primary: Time Till Relapse — 7; -8 Days to Relapse — p=<0.05
Phase 2 N=23 Caffeine and Cocaine
Cocaine Dependence
Primary: Visual Analog Scale Subjective Rating of Drug Effects — 8.65; 9.85; 13.65; 10.43 units on a scale
Phase 2 N=17 Open-Label Pilot Study of Lisdexamfetamine for Cocaine Dependence
Cocaine Dependence
Primary: Number of Participants Maintained on the Maximum Lisdexamfetamine Daily Dose. — 12 Participants
Phase 3 N=471 Stimulant Abuser Groups to Engage in 12-Step
Drug Abuse
Primary: Days of Stimulant Use — 2.35; 2.13 days of stimulant use — p=<0.05
Phase 2 N=50 Evaluation of Atomoxetine for Cocaine Dependence: A Pilot Trial
Substance Abuse
Primary: % Urine Samples Negative for Cocaine — .67; .74 percentage of positive urine samples
Phase 2 N=71 Modafinil vs Placebo for the Treatment of Methamphetamine Dependence
Methamphetamine Dependence
Primary: Clean Urine Drug Screen — 13.1; 12.7 Clean urine drug screens
Phase 2 N=52 Varenicline for Methamphetamine Dependence
Methamphetamine Dependence · Substance Abuse · Methamphetamine Abuse
Primary: End of Treatment Abstinence — 5; 4 Participants
Phase 1 N=12 An Assessment of the Safety of Varenicline in Methamphetamine-dependent Volunteers
Methamphetamine Addiction · Crystal Meth Addiction · Amphetamine Addiction
Primary: Systolic Blood Pressure — 126.4; 127.4 mm Hg
Phase 2 N=50 Psychopharmacology for Cocaine Dependence - Buspirone
Cocaine Dependence
Primary: Attentional Bias as Assessed by Score on the Stroop Task — -13.90333; 27.118; -9.361269; 15.35407 milliseconds
Phase 1 N=8 Behavioral Effects of Drugs (Inpatient): 40 [Methamphetamine, Methylphenidate, Duloxetine]
Methamphetamine Use Disorder
Primary: Reinforcing Effects of Methamphetamine Following Methylphenidate (0 mg; Placebo) Maintenance. — 0; 0; 3.33; 7.25 Trials Completed
Phase 1 N=30 Reinforcing Effects of Cocaine During Phendimetrazine Maintenance
Cocaine Use Disorder
Primary: Number of Times Cocaine Was Selected in the Presence of a Monetary Reward Alternative — .34; .24; 4.31; 3.9 Cocaine Choices
Phase 4 N=226 Stress Neuroadaptation in Tobacco Dependence
Nicotine Dependence
Primary: Overall Stressor Reactivity — 25.1; 22.5; 32.3; 16.9 microvolts
Phase 3 N=127 Multicenter Trial of Combined Pharmacotherapy to Treat Cocaine Dependence
Cocaine Dependence
Primary: Three Weeks of Cocaine Abstinence at End of Study — 9; 0 Participants
Phase 2 N=27 The Reinforcing Mechanisms of Smoking in Adult ADHD
ADHD
Primary: The Effects of ADHD Medication Versus Placebo on Cotinine Levels — 180.7; 274.0 ng/ml — p=<0.05
Phase 4 N=33 Brain Indices of Stimulant Treatment in Drug-Naive Youth at Risk for Substance Use Disorder
Attention Deficit Disorder With Hyperactivity · Conduct Disorder · Substance Abuse
Primary: Change in fMRI Measure — -0.957100; 0.572517; -0.139000; 1.876717 BOLD signal
Phase 1 N=93 Differential Responses to Drugs and Sweet Tastes
Bipolar II Disorder
Primary: Change in Subjective Effects as Assessed by Score on "Feel Drug", "Feel High", "Like Drug", and "Want More" Sub-scales of Drug Effects Questionnaire (DEQ). — 18.88…